Sasan Roayaie, Ghalib Jibara, Parissa Tabrizian, Joong‐Won Park, Jijin Yang, Lunan Yan, Myron Schwartz, Guohong Han, Francesco Izzo, Mishan Chen, Jean‐Frédéric Blanc, Philip Johnson, Masatoshi Kudo, Lewis R. Roberts, Morris Sherman – 11 February 2015 – Current guidelines recommend surgical resection as the primary treatment for a single hepatocellular cancer (HCC) with Child's A cirrhosis, normal serum bilirubin, and no clinically significant portal hypertension. We determined how frequently guidelines were followed and whether straying from them impacted survival.

Jean‐Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, Mohand Ait Ahmed, Setty Allam, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean‐Pierre Bronowicki, Jean‐Pierre Zarski, Odile Goria, Paul Calès, Jean‐Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean‐Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean‐Didier Grangé, Catherine Buffet, Yannick Bacq, Claire Wartelle, Thông Dao, Yves Benhamou, Christophe Pilette, Christine Silvain, Christos Christ

Hsi‐Hsun Lin, Susan Shin‐Jung Lee, Ming‐Lung Yu, Ting‐Tsung Chang, Chien‐Wei Su, Bor‐Shen Hu, Yaw‐Sen Chen, Chun‐Kai Huang, Chung‐Hsu Lai, Jiun‐Nong Lin, Jaw‐Ching Wu – 11 February 2015 – The emergence of hepatitis D virus (HDV) infection in the era of widespread HBV vaccination has not been described before. We aimed to investigate the changing epidemiology of HDV infection among high‐ and low‐risk populations after an outbreak of human immunodeficiency virus (HIV) infection among injection drug users (IDUs) in Taiwan.

Thomas D. Schiano, Tyler Bourgoise, Rosamond Rhodes – 4 February 2015 – In making liver transplantation (LT) listing decisions, transplant programs accept that very large differences in expected 5‐year posttransplant survival should matter and that small differences in expected survival should not matter. To date, the transplant community has not explicitly addressed the difficult question of how to make decisions when the differences are less dramatic.

C. Matthew Hawkins, Dennis W. W. Shaw, Patrick J. Healey, Simon P. Horslen, Andre A. S. Dick, Seth Friedman, Giridhar M. Shivaram – 3 February 2015 – The objective of this study was to determine which transabdominal ultrasound parameters correlate with portal vein stenosis (PVS) on percutaneous transhepatic portal venography in pediatric liver transplant patients. A retrospective review was performed of percutaneous transhepatic portal venograms performed between 2005 and 2013. The findings were compared to those from ultrasounds performed before venography and at the baseline.

Augusto Villanueva, Anna Portela, Sergi Sayols, Carlo Battiston, Yujin Hoshida, Jesús Méndez‐González, Sandrine Imbeaud, Eric Letouzé, Virginia Hernandez‐Gea, Helena Cornella, Roser Pinyol, Manel Solé, Josep Fuster, Jessica Zucman‐Rossi, Vincenzo Mazzaferro, Manel Esteller, Josep M. Llovet, on behalf of the HEPTROMIC Consortium – 2 February 2015 – Epigenetic deregulation has emerged as a driver in human malignancies. There is no clear understanding of the epigenetic alterations in hepatocellular carcinoma (HCC) and of the potential role of DNA methylation markers as prognostic biomarkers.

Vincent Montoya, Andrea D. Olmstead, Naveed Z. Janjua, Patrick Tang, Jason Grebely, Darrel Cook, P. Richard Harrigan, Mel Krajden – 2 February 2015 – The ability to classify acute versus chronic hepatitis C virus (HCV) infections at the time of diagnosis is desirable to improve the quality of surveillance information. The aim of this study was to differentiate acute from chronic HCV infections utilizing deep sequencing.

Qing Pang, Xin Sen Xu, Jing Yao Zhang, Kai Qu, Wei Chen, Chang Liu – 2 February 2015

Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbara, Michele Basso, Sara Vavassori, Antonio Craxì, Antonio Grieco, Carlo Cammà, Massimo Colombo – 2 February 2015 – Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects.

Alessandro Vitale, Michael Volk, Umberto Cillo – 31 January 2015